Immunotherapeutic approaches for cancer therapy: An updated review

References

• Abrams DI, Volberding PA. 1986. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol. 13:43–47.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Rai KR. 2003. Interferon in the treatment of hairy-cell leukemia. Best Pract Res Clin Haematol. 16:69–81.
   PubMed Web of Science ®Google Scholar
• Antonia S, Mule JJ, Weber JS. 2004. Current developments of immunotherapy in the clinic. Curr Opin Immunol. 16:130–136.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 17:2105–2116.
   PubMed Web of Science ®Google Scholar
• Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. 2010. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself. 1:314–322.
   PubMedGoogle Scholar
• Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760.
   PubMed Web of Science ®Google Scholar
• Bhutia SK, Mallick SK, Maiti TK. 2010. Tumour escape mechanisms and their therapeutic implications in combination tumour therapy. Cell Biol Int. 34:553–563.
   PubMed Web of Science ®Google Scholar
• Binder RJ, Han DK, Srivastava PK. 2000. CD91: a receptor for heat shock protein gp96. Nat Immunol. 1:151–155.
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. 2000. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60:1028–1034.
   PubMed Web of Science ®Google Scholar
• Bonifazi F, De Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, et al. 2001. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 98:3074–3081.
   PubMed Web of Science ®Google Scholar
• Borrebaeck CA. 1989. Strategy for the production of human monoclonal antibodies using in vitro activated B cells. J Immunol Methods. 123:157–165.
   PubMed Web of Science ®Google Scholar
• Breccia M, Lo-Coco F. 2011. Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. Expert Opin Biol Ther. 11: 225–234.
   PubMed Web of Science ®Google Scholar
• Burnet M. 1957. Cancer—A Biological Approach: III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J. 1:841.
   PubMed Web of Science ®Google Scholar
• Caley IJ, Betts MR, Irlbeck DM, Davis NL, Swanstrom R, Frelinger JA, Johnston RE. 1997. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol. 71:3031–3038.
   PubMed Web of Science ®Google Scholar
• Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, et al. 2010. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol. 2010: 956304.
   PubMedGoogle Scholar
• Chen D, Koido S, Li Y, Gendler S, Gong J. 2000. T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice. Breast Cancer Res Treat. 60:107–115.
   PubMed Web of Science ®Google Scholar
• Chen MS, Woodward WA, Behbod F, Peddibhotla S, Alfaro MP, Buchholz TA, Rosen JM. 2007. Wnt/β-catenin mediates radiation resistance of Sca1 + progenitors in an immortalized mammary gland cell line. J Cell Sci. 120:468–477.
   PubMed Web of Science ®Google Scholar
• Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J. 2001. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer. 93:539–548.
   PubMed Web of Science ®Google Scholar
• Cheuk AT, Chan L, Czepulkowski B, Berger SA, Yagita H, Okumura K, et al. 2006. Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunol Immunother. 55:68–75.
   PubMed Web of Science ®Google Scholar
• Costello RT, Gastaut JA, Olive D. 1999. Tumor escape from immune surveillance. Arch Immunol Ther Exp (Warsz). 47:83–88.
   PubMedGoogle Scholar
• Davila ML, Kloss CC, Gunset G, Sadelain M. 2013. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One. 8:e61338.
   PubMed Web of Science ®Google Scholar
• de Bruyn G, Rossini AJ, Chiu YL, Holman D, Elizaga ML, Frey SE, et al. 2004. Safety profile of recombinant canarypox HIV vaccines. Vaccine. 22:704–713.
   PubMed Web of Science ®Google Scholar
• De Giovanni C, Nicoletti G, Landuzzi L, Astolfi A, Croci S, Comes A, et al. 2004. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res. 64:4001–4009.
   PubMed Web of Science ®Google Scholar
• Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. 2002. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 20:2624–2632.
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Wahren B, Liu MA. 2005. DNA vaccines: progress and challenges. J Immunol. 175:633–639.
   PubMed Web of Science ®Google Scholar
• Doorbar J. 2006. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 110:525–541.
   PubMed Web of Science ®Google Scholar
• Dotti G, Savoldo B, Brenner M. 2009. Fifteen years of gene therapy based on chimeric antigen receptors: “are we nearly there yet?”. Hum Gene Ther. 20:1229–1239.
   PubMed Web of Science ®Google Scholar
• Dranoff G. 2003. GM-CSF-secreting melanoma vaccines. Oncogene. 22:3188–3192.
   PubMed Web of Science ®Google Scholar
• Draper SJ, Heeney JL. 2010. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 8:62–73.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 3:991–998.
   PubMed Web of Science ®Google Scholar
• Dutcher JP. 2011. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard. Oncology (Williston Park). 25:427–428.
   PubMed Web of Science ®Google Scholar
• Ehrlich PR, Himmelweit F. 1956. The collected papers of Paul Ehrlich. London:Pergamon Press.
   Google Scholar
• Essers MAG, Trumpp A. 2010. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol. 4:443–450.
   PubMed Web of Science ®Google Scholar
• Feili-Hariri M, Falkner DH, Morel PA. 2005. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. J Leukoc Biol. 78:656–664.
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Semino C, Spaggiari GM, Meta M, Mingari MC, Melioli G. 2000. Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates. Int Immunol. 12:1741–1747.
   PubMed Web of Science ®Google Scholar
• Finn OJ. 2006. Human tumor antigens, immunosurveillance, and cancer vaccines. Immunol Res. 36:73–82.
   PubMed Web of Science ®Google Scholar
• Finn OJ. 2008. Cancer immunology. N Engl J Med. 358:2704–2715.
   PubMed Web of Science ®Google Scholar
• Finn OJ. 2012. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 23 Suppl 8:viii6–9.
   PubMed Web of Science ®Google Scholar
• Flynn S, Stockinger B. 2003. Tumor and CD4 T-cell interactions: tumor escape as result of reciprocal inactivation. Blood. 101:4472–4478.
   PubMed Web of Science ®Google Scholar
• Frazer IH, Lowy DR, Schiller JT. 2007. Prevention of cancer through immunization: Prospects and challenges for the 21st century. Eur J Immunol. 37 Suppl 1:S148–155.
   PubMedGoogle Scholar
• Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 2:1096–1103.
   PubMed Web of Science ®Google Scholar
• Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F. 2004. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother. 53:963–977.
   PubMed Web of Science ®Google Scholar
• Garcia-Marquez MA, Shimabukuro-Vornhagen A, Theurich S, von Bergwelt-Baildon M. 2013. Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy? Immunotherapy. 5:1039–1042.
   PubMed Web of Science ®Google Scholar
• Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, et al. 2000. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol. 165:1705–1711.
   PubMed Web of Science ®Google Scholar
• Greiner JW, Zeytin H, Anver MR, Schlom J. 2002. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res. 62:6944–6951.
   PubMed Web of Science ®Google Scholar
• Group OMTS. 1985. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med. 313:337–342.
   PubMed Web of Science ®Google Scholar
• Han EQ, Li XL, Wang CR, Li TF, Han SY. 2013. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol. 6:47.
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge RB. 2010. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2:256–265.
   PubMed Web of Science ®Google Scholar
• Harrop R, Carroll MW. 2006. Viral vectors for cancer immunotherapy. Front Biosci. 11:804–817.
   PubMed Web of Science ®Google Scholar
• Hauschild A. 2009. Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations? Curr Oncol. 16:3–6.
   PubMed Web of Science ®Google Scholar
• Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, et al. 2000. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol. 164:5508–5514.
   PubMed Web of Science ®Google Scholar
• Hess PR, Boczkowski D, Nair SK, Snyder D, Gilboa E. 2006. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother. 55:672–683.
   PubMed Web of Science ®Google Scholar
• Huang SM, Bock JM, Harari PM. 1999. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59:1935–1940.
   PubMed Web of Science ®Google Scholar
• Igney FH, Krammer PH. 2002. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 71:907–920.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99:12293–12297.
   PubMed Web of Science ®Google Scholar
• Jacobs SA. 2007. Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects. Biologics. 1:215–227.
   PubMedGoogle Scholar
• Jager E, Jager D, Knuth A. 2002. Clinical cancer vaccine trials. Curr Opin Immunol. 14:178–182.
   PubMed Web of Science ®Google Scholar
• Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 321:522–525.
   PubMed Web of Science ®Google Scholar
• Jordan CT, Guzman ML, Noble M. 2006. Cancer stem cells. N Engl J Med. 355:1253–1261.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–422.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Darcy PK. 2013. Gene-engineered T cells for cancer therapy. Nat Rev Cancer. 13:525–541.
   PubMed Web of Science ®Google Scholar
• Kim CJ, Cormier J, Roden M, Gritz L, Mazzara GP, Fetsch P, et al. 1998. Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. Ann Surg Oncol. 5:64–76.
   PubMed Web of Science ®Google Scholar
• Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. 2005. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 11:1010–1020.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Houck K, Winer J, Ferrara N. 1992. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 7:53–64.
   PubMedGoogle Scholar
• Kim R, Emi M, Tanabe K. 2007. Cancer immunoediting from immune surveillance to immune escape. Immunology. 121:1–14.
   PubMed Web of Science ®Google Scholar
• Kirkwood J. 2002. Cancer immunotherapy: the interferon-α experience. Semin Oncol. 29:18–26.
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:495–497.
   PubMed Web of Science ®Google Scholar
• Kyi C, Postow MA. 2014. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 588:368–376.
   PubMed Web of Science ®Google Scholar
• Lambert PH, Liu M, Siegrist CA. 2005. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med. 11:S54–62.
   PubMed Web of Science ®Google Scholar
• Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM. 1993. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother. 37:255–263.
   PubMed Web of Science ®Google Scholar
• Li H, Jiang HJ, Ma MQ, Wei F, An XM, Ren XB. 2007. Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: antitumor activity comparing with that induced by autologous vaccine. Cancer Biother Radiopharm. 22:790–798.
   PubMed Web of Science ®Google Scholar
• Li Y, Bendandi M, Deng Y, Dunbar C, Munshi N, Jagannath S, et al. 2000. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood. 96:2828–2833.
   PubMed Web of Science ®Google Scholar
• Lollini PL, Cavallo F, Nanni P, Forni G. 2006. Vaccines for tumour prevention. Nat Rev Cancer. 6:204–216.
   PubMed Web of Science ®Google Scholar
• Lonberg N. 2008. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol. 20:450–459.
   PubMed Web of Science ®Google Scholar
• Mackett M, Smith GL, Moss B. 1982. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A. 79:7415–7419.
   PubMed Web of Science ®Google Scholar
• Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, et al. 1996. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest. 98:1633–1641.
   PubMed Web of Science ®Google Scholar
• Mellor AL, Munn D, Chandler P, Keskin D, Johnson T, Marshall B, et al. 2003. Tryptophan catabolism and T cell responses. Adv Exp Med Biol. 527:27–35.
   PubMed Web of Science ®Google Scholar
• Mesa C, Fernandez LE. 2004. Challenges facing adjuvants for cancer immunotherapy. Immunol Cell Biol. 82:644–650.
   PubMed Web of Science ®Google Scholar
• Meyer JP, Persad R, Gillatt DA. 2002. Use of bacille Calmette-Guerin in superficial bladder cancer. Postgrad Med J. 78:449–454.
   PubMed Web of Science ®Google Scholar
• Meyer T, Surber C, French LE, Stockfleth E. 2013. Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin Investig Drugs. 22:149–159.
   PubMed Web of Science ®Google Scholar
• Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P. 2003. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood. 101:977–982.
   PubMed Web of Science ®Google Scholar
• Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. 1993. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol. 11:1368–1375.
   PubMed Web of Science ®Google Scholar
• Mittler RS, Foell J, Mccausland M, Strahotin S, Niu L, Bapat A, Hewes LB. 2004. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Immunol Res. 29:197–208.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. 2004. Part I: Vaccines for solid tumours. Lancet Oncol. 5:681–689.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Marincola FM, Young HA. 2005. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol. 78:1043–1051.
   PubMed Web of Science ®Google Scholar
• Moran AE, Kovacsovics-Bankowski M, Weinberg AD. 2013. The TNFRs OX40, 4–1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol. 25:230–237.
   PubMed Web of Science ®Google Scholar
• Nencioni A, Muller MR, Grunebach F, Garuti A, Mingari MC, Patrone F, et al. 2003. Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. Cancer Gene Ther. 10:209–214.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Tonel G, Farkas A. 2005. Cancer vaccines: the next generation of tools to monitor the anticancer immune response. PLoS Med. 2:e339.
   Google Scholar
• Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, Rabbitts TH. 1985. A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature. 314:268–270.
   PubMed Web of Science ®Google Scholar
• Neville AM, Mackay AM, Westwood J, Turberville C, Laurence DJ. 1975. Human tumour-associated and tumour-specific antigens: some concepts in relation to clinical oncology. J Clin Pathol Suppl (Assoc Clin Pathol). 6:102–112.
   PubMedGoogle Scholar
• Newman KD, Elamanchili P, Kwon GS, Samuel J. 2002. Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res. 60:480–486.
   PubMed Web of Science ®Google Scholar
• Newstead C. 1998. Assessment of risk of cancer after renal transplantation. Lancet. 351:610–611.
   PubMed Web of Science ®Google Scholar
• Nguyen LV, Vanner R, Dirks P, Eaves CJ. 2012. Cancer stem cells: an evolving concept. Nat Rev Cancer. 12:133–143.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M, Ulmer JB. 2006. Microparticle-based technologies for vaccines. Methods. 40:10–19.
   PubMed Web of Science ®Google Scholar
• Oldfield V, Keating GM, Perry CM. 2005. Imiquimod: in superficial basal cell carcinoma. Am J Clin Dermatol. 6:195–200; discussion 201–202.
   PubMed Web of Science ®Google Scholar
• Oldham RK. 1983. Monoclonal antibodies in cancer therapy. J Clin Oncol. 1:582–590.
   PubMed Web of Science ®Google Scholar
• Pageau SC. 2009. Denosumab. MAbs. 1:210–215.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. 2013. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 39:38–48.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
   PubMed Web of Science ®Google Scholar
• Parmiani G, Pilla L, Maccalli C, Russo V. 2011. Autologous versus allogeneic cell-based vaccines? Cancer J. 17:331–336.
   PubMed Web of Science ®Google Scholar
• Pasche B. 2001. Role of transforming growth factor beta in cancer. J Cell Physiol. 186:153–168.
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 100:8372–8377.
   PubMed Web of Science ®Google Scholar
• Pijpers F, Faint R, Saini N. 2005. Therapeutic cancer vaccines. Nat Rev Drug Discov. 4:623–624.
   PubMed Web of Science ®Google Scholar
• Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. 1999. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity. 11:753–761.
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 83:435–445.
   PubMed Web of Science ®Google Scholar
• Rico MJ, Hall RP 3rd. 1989. Anti-idiotypic antibodies as vaccine candidates. The immune network. Arch Dermatol. 125:271–275.
   PubMedGoogle Scholar
• Riether C, Schurch C, Ochsenbein AF. 2012. Modulating CD27 signaling to treat cancer. Oncoimmunology. 1:1604–1606.
   PubMed Web of Science ®Google Scholar
• Riether C, Schurch C, Ochsenbein AF. 2013. From “magic bullets” to specific cancer immunotherapy. Swiss Med Wkly. 143:w13734.
   PubMed Web of Science ®Google Scholar
• Robinson HL, Pertmer TM. 2000. DNA vaccines for viral infections: basic studies and applications. Adv Virus Res. 55:1–74.
   PubMed Web of Science ®Google Scholar
• Roman LD, Wilczynski S, Muderspach LI, Burnett AF, O’Meara A, Brinkman JA, et al. 2007. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol. 106:558–566.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 10:909–915.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, et al. 1998. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst. 90:1894–1900.
   PubMed Web of Science ®Google Scholar
• Rutar FJ, Augustine SC, Kaminski MS, Wahl RL, Siegel JA, Colcher D. 2001. Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin Lymphoma. 2:164–172.
   PubMedGoogle Scholar
• Sadelain M, Brentjens R, Riviere I. 2013. The basic principles of chimeric antigen receptor design. Cancer Discov. 3:388–398.
   PubMed Web of Science ®Google Scholar
• Salazar-Onfray F. 1999. Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med Oncol. 16:86–94.
   PubMed Web of Science ®Google Scholar
• Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, et al. 2003. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 21:624–630.
   PubMed Web of Science ®Google Scholar
• Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, et al. 2005. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res. 65:2009–2017.
   PubMed Web of Science ®Google Scholar
• Sarry J-E, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, et al. 2011. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest. 121:384.
   PubMed Web of Science ®Google Scholar
• Schächinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, et al. 2004. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarctionfinal one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol. 44:1690–1699.
   PubMed Web of Science ®Google Scholar
• Schaer DA, Murphy JT, Wolchok JD. 2012. Modulation of GITR for cancer immunotherapy. Curr Opin Immunol. 24:217–224.
   PubMed Web of Science ®Google Scholar
• Schreiber TH, Raez L, Rosenblatt JD, Podack ER. 2010. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin Immunol. 22:105–112.
   PubMed Web of Science ®Google Scholar
• Schulenburg A, Herrmann H, Karlic H, Mirkina I, Hubmann R, Laffer S, et al. 2010. Neoplastic stem cells: current concepts and clinical perspectives. Crit Rev Oncol Hematol. 76:79–98.
   PubMed Web of Science ®Google Scholar
• Scott AM, Allison JP, Wolchok JD. 2012. Monoclonal antibodies in cancer therapy. Cancer Immun. 12:14.
   PubMedGoogle Scholar
• Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. 2008. Epitope landscape in breast and colorectal cancer. Cancer Res. 68:889–892.
   PubMed Web of Science ®Google Scholar
• Smith GP. 1985. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 228:1315–1317.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. 2012. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 379:39–46.
   PubMed Web of Science ®Google Scholar
• Sobol RE. 2006. The rationale for prophylactic cancer vaccines and need for a paradigm shift. Cancer Gene Ther. 13:725–731.
   PubMed Web of Science ®Google Scholar
• Srivastava PK. 2005. Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep. 7:104–108.
   PubMedGoogle Scholar
• Steinman RM, Banchereau J. 2007. Taking dendritic cells into medicine. Nature. 449:419–426.
   PubMed Web of Science ®Google Scholar
• Stevenson FK. 2004. DNA vaccines and adjuvants. Immunol Rev. 199:5–8.
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, Mccann KJ, et al. 2004. DNA vaccines to attack cancer. Proc Natl Acad Sci U S A. 101 Suppl 2:14646–14652.
   PubMed Web of Science ®Google Scholar
• Strand S, Galle PR. 1998. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today. 4:63–68.
   PubMedGoogle Scholar
• Strioga MM, Felzmann T, Powell DJ Jr., Ostapenko V, Dobrovolskiene NT, Matuskova M, et al. 2013. Therapeutic dendritic cell-based cancer vaccines: the state of the art. Crit Rev Immunol. 33:489–547.
   PubMed Web of Science ®Google Scholar
• Tabi Z, Man S. 2006. Challenges for cancer vaccine development. Adv Drug Deliv Rev. 58:902–915.
   PubMed Web of Science ®Google Scholar
• Tang DC, Devit M, Johnston SA. 1992. Genetic immunization is a simple method for eliciting an immune response. Nature. 356:152–154.
   PubMed Web of Science ®Google Scholar
• Tarhini A, Lo E, Minor DR. 2010. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 25:601–613.
   PubMed Web of Science ®Google Scholar
• Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, et al. 2008. Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 112:568–575.
   PubMed Web of Science ®Google Scholar
• Taylor DD, Taylor CG, Jiang CG, Black PH. 1988. Characterization of plasma membrane shedding from murine melanoma cells. Int J Cancer. 41:629–635.
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, van Den Brakel J, Pluyter M, Huang H, et al. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 104:1793–1800.
   PubMed Web of Science ®Google Scholar
• Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. 1995. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A. 92:11993–11997.
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, et al. 2002. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 99:1517–1526.
   PubMed Web of Science ®Google Scholar
• Triozzi PL, Allen KO, Carlisle RR, Craig M, Lobuglio AF, Conry RM. 2005. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res. 11: 4168–4175.
   PubMed Web of Science ®Google Scholar
• Vaklavas C, Forero-Torres A. 2012. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol. 3:209–225.
   PubMedGoogle Scholar
• Vazquez AM, Hernandez AM, Macias A, Montero E, Gomez DE, Alonso DF, et al. 2012. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol. 2:150.
   PubMedGoogle Scholar
• Vinay DS, Kwon BS. 2012. Immunotherapy of cancer with 4–1BB. Mol Cancer Ther. 11:1062–1070.
   PubMed Web of Science ®Google Scholar
• Vu T, Claret FX. 2012. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol. 2:62.
   PubMedGoogle Scholar
• Whiteside TL. 2005. Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system? Br J Cancer. 92:209–211.
   PubMed Web of Science ®Google Scholar
• Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, et al. 2004. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 364:141–148.
   PubMed Web of Science ®Google Scholar
• Yaddanapudi K, Mitchell RA, Eaton JW. 2013. Cancer vaccines: Looking to the future. Oncoimmunology. 2:e23403.
   PubMed Web of Science ®Google Scholar
• Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M, et al. 2005. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res. 11:5900–5911.
   PubMed Web of Science ®Google Scholar
• Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. 1999. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59:1236–1243.
   PubMed Web of Science ®Google Scholar
• Yee C. 2013. Adoptive T-cell therapy for cancer: boutique therapy or treatment modality? Clin Cancer Res. 19:4550–4552.
   PubMed Web of Science ®Google Scholar
• Yu M, Finn OJ. 2006. DNA vaccines for cancer too. Cancer Immunol Immunother. 55:119–130.
   PubMed Web of Science ®Google Scholar
• Zent CS, Secreto CR, Laplant BR, Bone ND, Call TG, Shanafelt TD, et al. 2008. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res. 32:1849–1856.
   PubMed Web of Science ®Google Scholar
• Zhou G, Lu Z, Mccadden JD, Levitsky HI, Marson AL. 2004. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med. 200:1581–1592.
   PubMed Web of Science ®Google Scholar
• Zhou H, Luo Y, Lo JF, Kaplan CD, Mizutani M, Mizutani N, et al. 2005. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc Natl Acad Sci U S A. 102:10846–10851.
   PubMed Web of Science ®Google Scholar
• Zou W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 5:263–274.
   PubMed Web of Science ®Google Scholar
• zum Buschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H. 2002. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 62:2244–2247.
   PubMed Web of Science ®Google Scholar